Journal
JOURNAL OF CONTROLLED RELEASE
Volume 143, Issue 3, Pages 367-373Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2010.01.008
Keywords
Poorly soluble drugs; Indomethacin; Lipid-based oral delivery; In-vitro dissolution; In-vivo pharmacokinetics
Funding
- Australian Research Council [DP0558920]
- Australian Research Council [DP0558920] Funding Source: Australian Research Council
Ask authors/readers for more resources
We report on a porous silica-lipid hybrid microcapsule (SLH) oral delivery system for indomethacin fabricated from Pickering emulsion templates, where the drug forms an electrostatic complex with cationic lipid present in the oil phase. Dry SLH microcapsules prepared either by spray drying (similar to 1-5 mu m) or phase coacervation (20-50 mu m) exhibit a specific internal porous matrix structure with pore diameters in the range of 20 to 100 nm. Dissolution studies under sink conditions and in the presence of electrolytes revealed a decreased extent of dissolution; this confirms the lipophilic nature the drug-lipid complex and its location in the oil phase. Orally dosed in-vivo studies in rats showed complete drug absorption and statistically higher fasted state bioavailability (F) (p < 0.05) in comparison to aqueous suspensions and o/w submicron emulsions of indomethacin. It is postulated that the SLH microcapsules improve oral absorption via complete solubilisation of drug-lipid electrostatic complexes during enzymatic lipolysis in the GI track. Crown Copyright (C) 2010 Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available